- Home
- EWTX vs DCOM Comparison
EWTX vs DCOM Comparison
Compare EWTX & DCOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- DCOM
- Stock Information
- Founded
- EWTX 2017
- DCOM 1864
- Country
- EWTX United States
- DCOM United States
- Employees
- EWTX N/A
- DCOM N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- DCOM Major Banks
- Sector
- EWTX Health Care
- DCOM Finance
- Exchange
- EWTX Nasdaq
- DCOM Nasdaq
- Market Cap
- EWTX 1.2B
- DCOM 1.2B
- IPO Year
- EWTX 2021
- DCOM 1996
- Fundamental
- Price
- EWTX $14.58
- DCOM $26.58
- Analyst Decision
- EWTX Buy
- DCOM Buy
- Analyst Count
- EWTX 8
- DCOM 4
- Target Price
- EWTX $40.13
- DCOM $33.88
- AVG Volume (30 Days)
- EWTX 1.2M
- DCOM 268.9K
- Earning Date
- EWTX 05-08-2025
- DCOM 04-22-2025
- Dividend Yield
- EWTX N/A
- DCOM 3.76%
- EPS Growth
- EWTX N/A
- DCOM N/A
- EPS
- EWTX N/A
- DCOM 0.62
- Revenue
- EWTX N/A
- DCOM $295,419,000.00
- Revenue This Year
- EWTX N/A
- DCOM $54.60
- Revenue Next Year
- EWTX N/A
- DCOM $15.74
- P/E Ratio
- EWTX N/A
- DCOM $42.53
- Revenue Growth
- EWTX N/A
- DCOM N/A
- 52 Week Low
- EWTX $10.60
- DCOM $17.49
- 52 Week High
- EWTX $38.12
- DCOM $37.60
- Technical
- Relative Strength Index (RSI)
- EWTX 41.67
- DCOM 53.12
- Support Level
- EWTX $13.82
- DCOM $25.92
- Resistance Level
- EWTX $17.30
- DCOM $26.92
- Average True Range (ATR)
- EWTX 1.02
- DCOM 0.80
- MACD
- EWTX 0.32
- DCOM 0.22
- Stochastic Oscillator
- EWTX 30.43
- DCOM 86.12
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About DCOM Dime Community Bancshares Inc.
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.